Pharmacogenomics in ophthalmology

Stephen Schwartz, Tomomi Higashide, Milam A. Brantley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pharmacogenomics is an evolving research discipline within ophthalmology, but genetic data are not currently used to guide daily clinical decisions. Ophthalmic pharmacogenomic research has thus far focused on open-angle glaucoma (OAG) and age-related macular degeneration (AMD), two common and worldwide causes of visual loss. In the treatment of OAG and allied disorders, there are reported associations between various polymorphisms in adrenergic receptor genes and topical β-antagonists as well as between the prostaglandin receptor gene and a topical prostaglandin analogue. In the treatment of exudative AMD, there are reported associations between AMD-associated genes, such as complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), and the efficacy of different treatment modalities including photodynamic therapy and intra- vitreal vascular endothelial growth factor (VEGF) antagonists. The steroid response associated with ophthalmic corticosteroids has been investigated, but no definite genetic associations have been reported. As additional pharmacogenomic trials are reported, the precise relationship between genotype and treatment response may become clearer.

Original languageEnglish (US)
Title of host publicationOmics for Personalized Medicine
PublisherSpringer India
Pages761-772
Number of pages12
ISBN (Print)9788132211846, 9788132211839
DOIs
StatePublished - Jan 1 2013

Fingerprint

Pharmacogenetics
Macular Degeneration
Ophthalmology
Open Angle Glaucoma
Prostaglandin Receptors
Genes
Synthetic Prostaglandins
Complement Factor H
Photochemotherapy
Research
Adrenergic Receptors
Vascular Endothelial Growth Factor A
Adrenal Cortex Hormones
Therapeutics
Steroids
Genotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schwartz, S., Higashide, T., & Brantley, M. A. (2013). Pharmacogenomics in ophthalmology. In Omics for Personalized Medicine (pp. 761-772). Springer India. https://doi.org/10.1007/978-81-322-1184-6_32

Pharmacogenomics in ophthalmology. / Schwartz, Stephen; Higashide, Tomomi; Brantley, Milam A.

Omics for Personalized Medicine. Springer India, 2013. p. 761-772.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schwartz, S, Higashide, T & Brantley, MA 2013, Pharmacogenomics in ophthalmology. in Omics for Personalized Medicine. Springer India, pp. 761-772. https://doi.org/10.1007/978-81-322-1184-6_32
Schwartz S, Higashide T, Brantley MA. Pharmacogenomics in ophthalmology. In Omics for Personalized Medicine. Springer India. 2013. p. 761-772 https://doi.org/10.1007/978-81-322-1184-6_32
Schwartz, Stephen ; Higashide, Tomomi ; Brantley, Milam A. / Pharmacogenomics in ophthalmology. Omics for Personalized Medicine. Springer India, 2013. pp. 761-772
@inbook{6019d3be1eb94a028eb0c53ff8c7eeb6,
title = "Pharmacogenomics in ophthalmology",
abstract = "Pharmacogenomics is an evolving research discipline within ophthalmology, but genetic data are not currently used to guide daily clinical decisions. Ophthalmic pharmacogenomic research has thus far focused on open-angle glaucoma (OAG) and age-related macular degeneration (AMD), two common and worldwide causes of visual loss. In the treatment of OAG and allied disorders, there are reported associations between various polymorphisms in adrenergic receptor genes and topical β-antagonists as well as between the prostaglandin receptor gene and a topical prostaglandin analogue. In the treatment of exudative AMD, there are reported associations between AMD-associated genes, such as complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), and the efficacy of different treatment modalities including photodynamic therapy and intra- vitreal vascular endothelial growth factor (VEGF) antagonists. The steroid response associated with ophthalmic corticosteroids has been investigated, but no definite genetic associations have been reported. As additional pharmacogenomic trials are reported, the precise relationship between genotype and treatment response may become clearer.",
author = "Stephen Schwartz and Tomomi Higashide and Brantley, {Milam A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-81-322-1184-6_32",
language = "English (US)",
isbn = "9788132211846",
pages = "761--772",
booktitle = "Omics for Personalized Medicine",
publisher = "Springer India",

}

TY - CHAP

T1 - Pharmacogenomics in ophthalmology

AU - Schwartz, Stephen

AU - Higashide, Tomomi

AU - Brantley, Milam A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Pharmacogenomics is an evolving research discipline within ophthalmology, but genetic data are not currently used to guide daily clinical decisions. Ophthalmic pharmacogenomic research has thus far focused on open-angle glaucoma (OAG) and age-related macular degeneration (AMD), two common and worldwide causes of visual loss. In the treatment of OAG and allied disorders, there are reported associations between various polymorphisms in adrenergic receptor genes and topical β-antagonists as well as between the prostaglandin receptor gene and a topical prostaglandin analogue. In the treatment of exudative AMD, there are reported associations between AMD-associated genes, such as complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), and the efficacy of different treatment modalities including photodynamic therapy and intra- vitreal vascular endothelial growth factor (VEGF) antagonists. The steroid response associated with ophthalmic corticosteroids has been investigated, but no definite genetic associations have been reported. As additional pharmacogenomic trials are reported, the precise relationship between genotype and treatment response may become clearer.

AB - Pharmacogenomics is an evolving research discipline within ophthalmology, but genetic data are not currently used to guide daily clinical decisions. Ophthalmic pharmacogenomic research has thus far focused on open-angle glaucoma (OAG) and age-related macular degeneration (AMD), two common and worldwide causes of visual loss. In the treatment of OAG and allied disorders, there are reported associations between various polymorphisms in adrenergic receptor genes and topical β-antagonists as well as between the prostaglandin receptor gene and a topical prostaglandin analogue. In the treatment of exudative AMD, there are reported associations between AMD-associated genes, such as complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), and the efficacy of different treatment modalities including photodynamic therapy and intra- vitreal vascular endothelial growth factor (VEGF) antagonists. The steroid response associated with ophthalmic corticosteroids has been investigated, but no definite genetic associations have been reported. As additional pharmacogenomic trials are reported, the precise relationship between genotype and treatment response may become clearer.

UR - http://www.scopus.com/inward/record.url?scp=84956753285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956753285&partnerID=8YFLogxK

U2 - 10.1007/978-81-322-1184-6_32

DO - 10.1007/978-81-322-1184-6_32

M3 - Chapter

SN - 9788132211846

SN - 9788132211839

SP - 761

EP - 772

BT - Omics for Personalized Medicine

PB - Springer India

ER -